时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and…
方法
These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits.
核心结论
Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this…
局限
While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny.
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：代谢—器官轴是干预安全性的主要约束面。 ｜ 价值分 1.8/5（★★☆☆☆）
全文来源
未取到全文 → 本卡为摘要级解读，未核验全文
原文题录
- 英文标题：Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
- 期刊与标识：Journal of the American Geriatrics Society · PMID 42952307 · DOI 10.1111/jgs.70769
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。